Advertisement starts (Tiscali)
The move gets U.S.-based Schering-Plough a near $5 billion-a-year (2.5 billion pound) business in women s health, central nervous system drugs and animal medicine, and marks the breakup of one of Europe s last hybrid chemical-pharmaceutical companies.